Pharmacological modulators that can coactivate TrkB signaling-mediated cell survival and Nrf2-ARE antioxidant systems offer promise for the treatment of diseases associated with OS-associated brain degeneration. Here, NFE2L2 is linked to neurodegenerative disease.